RESUMO
Human papillomavirus causes anal condylomata, high-grade anal intraepithelial neoplasia, and anal squamous cell cancer. We found high-grade intraepithelial neoplasia or squamous cell cancer in 75 (47%) of 159 HIV-seropositive men who have sex with men (MSM) and in 42 (26%) of 160 HIV-seronegative MSM with anal condylomata meriting surgery (P<.001, determined by use of the chi(2) test). Anal condylomata in MSM often harbor high-grade intraepithelial neoplasia and squamous cell cancer.
Assuntos
Doenças do Ânus/complicações , Neoplasias do Ânus/epidemiologia , Carcinoma de Células Escamosas/epidemiologia , Condiloma Acuminado/complicações , Homossexualidade Masculina , Infecções por Papillomavirus/complicações , Adolescente , Adulto , Idoso , Alphapapillomavirus , Doenças do Ânus/cirurgia , Doenças do Ânus/virologia , Neoplasias do Ânus/complicações , Neoplasias do Ânus/patologia , Carcinoma de Células Escamosas/complicações , Carcinoma de Células Escamosas/patologia , Estudos de Coortes , Condiloma Acuminado/cirurgia , Condiloma Acuminado/virologia , Soronegatividade para HIV , Soropositividade para HIV/complicações , Humanos , Masculino , Pessoa de Meia-Idade , Invasividade Neoplásica , Estudos Retrospectivos , Adulto JovemRESUMO
BACKGROUND: High-risk human papillomavirus (hrHPV) causes virtually all cervical cancers. Trans masculine (TM) people (those assigned female at birth who identify with a gender other than female) have low uptake of conventional cervical cancer screening. Self-collected hrHPV DNA testing has high levels of acceptability among cisgender (non-transgender) females and may support increased cervical cancer screening uptake in TM individuals. OBJECTIVE: To assess the test performance and acceptability of self-collected vaginal specimens in comparison to provider-collected cervical swabs for hrHPV DNA detection in TM individuals ages 21-64 years. METHODS: Between March 2015-September 2016, 150 TM participants with a cervix (mean age = 27.5 years; SD = 5.7) completed a one-time study visit comprised of a self-report survey, self-collected vaginal HPV DNA swab, clinician-administered cervical HPV swab, and brief interview on acceptability of clinical procedures. Participants were randomized to complete either self- or provider-collection first to minimize ordering effects. Self- and provider-collected samples were tested for 13 hrHPV DNA types using a DNA Hybridization Assay. The primary outcome variable was the concordance (kappa statistic) and performance (sensitivity, specificity) of self-collected vaginal HPV DNA specimens versus provider-collected cervical HPV swabs as the gold standard. RESULTS: Of the 131 participants completing both the self- and provider-collected HPV tests, 21 cases of hrHPV were detected by the provider cervical swab (gold standard; 16.0% hrHPV prevalence); 15 of these cases were accurately detected by the self-collected vaginal swab (71.4% concordance) (Kappa = 0.75, 95% Confidence Interval [CI]: 0.59, 0.92; p<0.001). Compared to the provider-collected cervical hrHPV DNA sample (gold standard), the self-collected vaginal hrHPV DNA test demonstrated a sensitivity of 71.4% (95% CI: 0.52, 0.91; p = 0.0495) and specificity of 98.2% (95% CI: 0.96, 1.00; p<0.0001). Over 90% of participants endorsed a preference for the self-collected vaginal swab over provider-collected cervical swab. CONCLUSION: Self-collected vaginal swabs are highly acceptable to TM as a means to test for hrHPV DNA. Test performance of this self-collection method for hrHPV detection in TM is consistent with previous studies in cisgender females. Self-collected vaginal swab testing for hrHPV DNA represents a reasonable and patient-centered strategy for primary cervical cancer screening in TM patients unwilling to undergo provider collection of specimens via speculum exam.
Assuntos
DNA Viral , Papillomaviridae/genética , Infecções por Papillomavirus/diagnóstico , Autocuidado , Transexualidade/virologia , Esfregaço Vaginal/métodos , Adulto , Detecção Precoce de Câncer/métodos , Feminino , Humanos , Entrevistas como Assunto , Masculino , Pessoa de Meia-Idade , Infecções por Papillomavirus/epidemiologia , Infecções por Papillomavirus/virologia , Aceitação pelo Paciente de Cuidados de Saúde , Prevalência , Sensibilidade e Especificidade , Pessoas Transgênero/psicologia , Transexualidade/epidemiologia , Transexualidade/psicologia , Neoplasias do Colo do Útero/diagnóstico , Neoplasias do Colo do Útero/virologia , Adulto JovemRESUMO
The incidence of human papillomavirus (HPV)-related anal squamous cell carcinoma is increasing. It is likely that long-standing HIV-related immunosuppression plays a significant role in the pathogenesis of anal carcinoma; however, a direct HIV-HPV interaction has also been implicated. Using cervical cancer prevention as a paradigm, anal Pap smear screening as part of routine HIV preventive care has been proposed to detect and treat precancerous anal lesions in the hope of decreasing anal cancer rates. All HIV-positive patients with invasive cancer of the anal canal, particularly those with CD4+ cell counts greater than 200/microL and those receiving HAART, should be managed in the same manner as their HIV-negative counterparts.
Assuntos
Neoplasias do Ânus/patologia , Carcinoma de Células Escamosas/patologia , Infecções por HIV/epidemiologia , Papillomaviridae/isolamento & purificação , Infecções por Papillomavirus/epidemiologia , Lesões Pré-Cancerosas/patologia , Neoplasias do Ânus/epidemiologia , Biópsia por Agulha , Carcinoma de Células Escamosas/epidemiologia , Feminino , Infecções por HIV/diagnóstico , Humanos , Imuno-Histoquímica , Incidência , Masculino , Programas de Rastreamento , Infecções por Papillomavirus/diagnóstico , Proctoscopia , Prognóstico , Medição de Risco , Análise de Sobrevida , Estados Unidos/epidemiologiaRESUMO
We compared the pathological diagnoses obtained by anal Papanicolaou (Pap) smear with those obtained by anal biopsy or by surgical excision for 153 men who have sex with men (MSM). Analysis of these paired specimens showed that anal Pap smears were an inaccurate predictor of high-grade anal dysplasia, regardless of human immunodeficiency virus (HIV) serostatus. The presence of any abnormal anal cytological finding indicates a potential for high-grade dysplasia on histological examination of MSM.
Assuntos
Neoplasias do Ânus/patologia , Soropositividade para HIV , Homossexualidade Masculina , Doenças do Ânus/epidemiologia , Doenças do Ânus/patologia , Neoplasias do Ânus/epidemiologia , Biópsia , Humanos , Masculino , Teste de PapanicolaouAssuntos
Infecções Oportunistas Relacionadas com a AIDS/induzido quimicamente , Linfogranuloma Venéreo/diagnóstico , Proctite/diagnóstico , Infecções Oportunistas Relacionadas com a AIDS/tratamento farmacológico , Adulto , Antibacterianos/administração & dosagem , Antibacterianos/uso terapêutico , Doxiciclina/administração & dosagem , Doxiciclina/uso terapêutico , Eritromicina/administração & dosagem , Eritromicina/uso terapêutico , Homossexualidade Masculina , Humanos , Linfogranuloma Venéreo/tratamento farmacológico , Masculino , Proctite/tratamento farmacológicoRESUMO
OBJECTIVE: To evaluate prospectively the safety of the infrared coagulator (IRC) as a treatment for anal high-grade squamous intraepithelial lesions (HSILs) in HIV-infected individuals and to seek preliminary evidence for efficacy. METHODS: HIV-infected patients with =3 biopsy-proven internal anal HSILs received office-based treatment with the IRC at participating AIDS Malignancy Consortium sites. Treatments were performed during high-resolution anoscopy (HRA) under local anesthesia. Patients were reevaluated at 3 months, and persistent lesions could be retreated. Patients were evaluated every 3 months for a year with anal cytology and HRA with biopsy. Human papillomavirus (HPV) DNA was measured at baseline and at follow-up using MY09/MY11 L1 polymerase chain reaction. RESULTS: A total of 44 HSILs were treated from 16 men and 2 women. HPV 16 was the most common HPV type identified. There was no consistent change in HPV type or viral load in patients before and after treatment with the IRC. No procedure-related severe adverse events were reported. Twelve patients reported mild or moderate anal/rectal pain or bleeding. CONCLUSIONS: The IRC is a well-tolerated method of treating discrete anal canal HSILs in HIV-infected patients. A larger study to characterize its efficacy better in the management of HSILs in HIV-infected individuals is warranted.